RTP Mobile Logo
Exploring Current Considerations and Promising Investigational Approaches for Patients with Myelodysplastic Syndromes (Webinar Video Proceedings)
Released September 2022

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman. Published September 28, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of myelodysplastic syndromes.

    LEARNING OBJECTIVES

    • Recognize the value of molecular testing for patients with myelodysplastic syndromes (MDS), and determine how various genetic alterations may affect MDS classification and risk assessment.
    • Evaluate the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for lower- and higher-risk MDS.
    • Recognize the FDA-approved indication for oral hypomethylating agent therapy for intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
    • Describe the biologic rationale for and available research findings with Bcl-2-targeted therapy for patients with high-risk MDS, and appraise the potential role of this strategy in current and future clinical care.
    • Develop an understanding of the mechanisms of action of and available data with investigational therapeutic approaches for higher-risk MDS in order to prepare for their potential availability in routine practice.
    • Implement a plan to manage the side effects associated with approved and investigational therapies for MDS to support quality of life and continuation of treatment.
    • Recall the design of ongoing clinical trials for low- and high-risk MDS, and counsel appropriate patients about the potential benefits of participation.

    ACCREDITATION STATEMENT
    Medical Learning Institute, Inc. (MLI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SOHO2022/MDS/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/SOHO2022/MDS/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SOHO2022/MDS/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/SOHO2022/MDS.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Guillermo Garcia-Manero, MD
    McCredie Professor of Medicine
    Chief, Section of MDS
    Vice Chair, Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No relevant conflicts of interest to disclose.

    Gail J Roboz, MD
    Director, Clinical and Translational Leukemia Programs
    Professor of Medicine
    Weill Cornell Medical College
    NewYork-Presbyterian Hospital
    New York, New York

    Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, bluebird bio, Blueprint Medicines, Bristol-Myers Squibb Company, Catamaran Bio, Celgene Corporation, GlaxoSmithKline, Helsinn Healthcare SA, Janssen Biotech Inc, Jasper Therapeutics Inc, Jazz Pharmaceuticals Inc, Mesoblast, Novartis, Pfizer Inc, Roche Laboratories Inc, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc (IRC Chair); Research Support: Janssen Biotech Inc.

    David Sallman, MD
    Assistant Member
    Malignant Hematology
    Moffitt Cancer Center
    Tampa, Florida

    Advisory Committee: AvenCell Therapeutics Inc, bluebird bio, Bristol-Myers Squibb Company, Intellia Therapeutics, Jasper Therapeutics Inc, Kite, A Gilead Company, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Affimed GmbH, Gilead Sciences Inc, Intellisphere LLC, Molecular Partners, Precigen Inc, Takeda Pharmaceuticals USA Inc, Zentalis Pharmaceuticals; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Incyte Corporation, Servier Pharmaceuticals LLC.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program has been supported by an independent educational grant from Gilead Sciences, Inc.

    Release date: September 2022
    Expiration date: September 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):